According to a report by journalist Alex Berenson, Moderna has halted a clinical trial for a new mRNA ‘vaccine’ due to a suspected case of myocarditis in a trial participant.

“Moderna today halted dosing for adolescents in its Phase 1 clinical trial of its Epstein-Barr virus vaccine after a suspected case of myocarditis in a trial participant,” Berenson wrote Thursday.

The biotechnology company did not publicly disclose the trial halt, Berenson says.


*Image from Alex Berenson X post*

Moderna has a lengthy list of mRNA ‘vaccines’ up the pipe, including Epstein-Barr virus.

The clinical trial halt would surely raise awareness to the adverse health events caused by mRNA technology.

Thus, Moderna doesn’t want news of a suspected case of myocarditis from a new ‘vaccine,’ expected to generate billions in profit, to go public.

Alex Berenson writes in Unreported Truths:

The case “necessitates an immediate suspension of all dosing for ALL adolescents,” an investigator at the company that is supervising the trial for Moderna wrote, adding, “Please confirm understanding and receipt of this urgent communication.”

The trial subjects should continue to be monitored for safety, the investigator wrote. About 150 adolescents are in the trial, along with 272 people aged 18-30.

A person not employed by Moderna, which makes the Spikevax Covid vaccine, provided the email to Unreported Truths.

Moderna did not disclose the trial halt, which occurred before stock markets opened for trading Thursday, to investors. Moderna stock is down about 85 percent from its highs in 2021, as sales of Spikevax lag, but it remains among the most valuable biotechnology companies, with a $30 billion market value.

The Epstein-Barr virus, which causes mononucleosis, is one of Moderna’s leading candidates for new vaccines. The company has told investors it could reach billions of dollars in sales a year.

But the trial halt raises questions for Moderna and mRNA jabs that go far beyond the Epstein-Barr vaccine – officially called mRNA-1189 – alone.


“Reupping this for those who missed it last night: @moderna_tx has been forced to halt a clinical trial of its mRNA vaccine for the Epstein-Barr virus in adolescents after a trial subject developed a suspected case of myocarditis. Moderna did not publicly disclose the halt,” Berenson wrote Friday.

The company’s stocks have steadily declined in recent weeks due to plummeting demand for the experimental mRNA COVID-19 shots.


Moderna on Thursday posted a steep loss for the third quarter as it recorded a large write-down due to unused doses of its Covid vaccine, its only marketable product, and unveiled plans to scale back production of the shot.

Shares of Moderna closed 6% lower on Thursday.

Moderna’s total revenue for the period topped Wall Street’s expectations, even amid plummeting demand for its shot. Its outlook for next year, however, came in lower than what analysts were projecting.

Here’s what Moderna reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv:

  • Loss per share: $9.53. That may not be comparable to the $1.93 per share expected by analysts.
  • Revenue: $1.83 billion vs. $1.40 billion expected

Moderna posted a net loss of $3.63 billion, or $9.53 per share, for the quarter. That compares with net income of $1.04 billion, or $2.53 per share, reported during the year-ago period.

The company said the loss was primarily driven by $3.1 billion in mostly non-cash charges related to tax allowances and changing its manufacturing footprint. The resizing, which resulted in $1.4 billion in charges during the third quarter, aims to make the company’s Covid vaccine profitable in 2024 and beyond, Moderna CEO Stéphane Bancel said in a statement.

Join The Conversation. Leave a Comment.

We have no tolerance for comments containing violence, racism, profanity, vulgarity, doxing, or discourteous behavior. If a comment is spam, instead of replying to it please click the ∨ icon below and to the right of that comment. Thank you for partnering with us to maintain fruitful conversation.